Table 12.

Subsequent remission and survival from observational studies describing treatment patterns

Study	AML population	Mean age, years	RR sample size	Data collection years	Patients achieving subsequent remission, %	Cohort survival from RR date	Survival by treatment from RR date
Bejanyan et al. 2015 [68]	Relapsed	32 (median)	1788	1990-2010	15	NR	Survival >1 year post-relapse, % of those treated with following regimens:
							Chemotherapy alone, 21
							Second HSCT ± chemotherapy and/or DLI, 44
							DLI ± chemotherapy, 14
							BSC only, 8
El-Ghammaz & El-Razzaz 2018 [59]	Relapsed	42	43	2010-2017	25.6	Mean, 5.14 months	NR
Sauer et al. 2015 [74]	Relapsed	52 (median)	108	2000-2013	NR	Median, 4.3 months	Survival >1 year post-relapse, % of those treated with following regimens:
							Intensive chemotherapy, 34.4
							Intensive chemotherapy + stem cell boost, 29.0
							Palliative chemotherapy, 3.6
							HSCT, 26.3
							Chemotherapy + DLI, 0
							Immunosuppressive tapering + DLI, 100a
Wattad et al. 2017 [114]	RR	55 (median)b	1025	1993-2009	36	NR	30-day:
		64 (median)c					HiDAC-based, 96.9
							Standard 7+3, 100
							Other intensive chemotherapy, 98.8
							Experimental, 100
							Primary allo-HSCT, 100
Zhang et al. 2017 [117]	Relapsed	NR	1726	2010-2014	NR	30-day, 80.4%	NR
						60-day, 66.4%

Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; BSC, best supportive care; DLI, donor lymphocyte infusion; HiDAC, high-dose cytarabine; HMA, hypomethylating agent; HSCT, hematopoietic stem cell transplantation; NR, not reported; RR, relapsed or refractory.

^aOne patient received this treatment and survived at least 1 year after initial relapse.

^bMedian age provided for the intensive treatment arm (n=875).

^cMedian age provided for the non-intensive treatment arm (n=150).